CD8+ CTLs from B-I09-treated mice demonstrated tumor killing equal to CTLs from vehicle-treated recipients, and both were significantly more potent than CD8+ CTLs from unvaccinated controls (Figure 7H). Here, CD8A is linked to neoplasm.